Compare Huntington Bancshares Incorporated (HBAN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs State Street SPDR S&P Biotech ETF — how do they compare? Huntington Bancshares Incorporated trades at $18.12 (market cap $36.62B), while State Street SPDR S&P Biotech ETF trades at $154.14. The key difference: Huntington Bancshares Incorporated pays a 3.43% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Huntington Bancshares Incorporated nearer its low. Which is the better fit depends on your goals.
| HBAN | XBI | |
|---|---|---|
Market Cap | $36.62B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $19.27 | $164.28 |
52-Week Low | $15.02 | $85.16 |
Dividend Yield | 3.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $18.07, down 0.99% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company reported Q1 2026 EPS of $0.25, beating expectations, with revenue growth to $8.13 billion in 2025. Recent news highlights expansion in Texas and a strong fintech partnership award.
HBAN presents a mixed outlook; analyst consensus is a Buy with a $20.25 price target, implying upside, but risks include integration challenges from acquisitions and competitive pressures in regional banking. Earnings growth and margin stability are key catalysts, though debt levels have risen steadily.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
